Oral iron chelators: New opportunities and new dilemmas

Haematologica

Volumn 91, Issue 10, 2006, Pages 1307-1312

  Hershko, Chaim ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; CREATININE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGRANULOCYTOSIS; ALLERGY; ARTHRALGIA; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG HALF LIFE; DRUG MEGADOSE; EDITORIAL; EYE DISEASE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEARING IMPAIRMENT; HEART PROTECTION; HUMAN; IRON OVERLOAD; LIVER BIOPSY; MEDICAL ASSESSMENT; MORTALITY; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PLASMA HALF LIFE; RASH; SIDE EFFECT; SIDEROSIS; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANIMALS; DEFEROXAMINE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; SIDEROSIS;

EID: 33749990010     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (35)

1. Andrews NC. A genetic view of iron homeostasis. Semin Hematol 2002; 39:227-34.
2. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102:783-8.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-93.
4. Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, et al. Phase II clinical evaluation of deferasirox (Exjade, ICL670) a once-daily oral chelatgin agent, in paediatric patients with β-thalassaemia major. Haematologica 2006; 91:XXX.
5. Liu ZD, Liu DY, Hider RC. Iron chelator chemistry. Adv Exp Med Biol 2002; 509: 141-66.
6. Hershko C, Link G, Konijn AM, Cabantchik ZI. Objectives and mechanism of iron chelation therapy. Ann N Y Acad Sci 2005;1054:124-35.
7. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and sucsceptibility to chelation Blood 2003;102:2670-7.
8. Porter JB. Monitoring and treatment of iron overload: state of the art and new approaches. Semin Hematol 2005; 42: S14-8.
9. St. Pierre TG, Clark PR, Chua-anusom W, Fleming AJ, Jeffrey GP, Olynyk JK, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105: 855-61.
10. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331:567-73.
11. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-8.
12. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9.
13. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127: 348-55.
14. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia. Blood 2000;95:1229-36.
15. Miskin H, Yaniv I, Berant M, Hershko C, Tamary H. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation Eur J Haematol 2003; 70:398-403.
16. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004;104:263-9.
17. Modell B, Khan M, Darlison M: Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355:2051-2.
18. Cunningham MJ, Macklin EA, Neufeld EJ. Complications of β-thalassemia major in North America. Blood 2004; 104:34-9.
19. Barman Balfour JA, Foster RH. Deferiprone. A review of its clinical potential in iron overload in β-thalassaemia major and other transfusion-dependent diseases. Drugs 1999;58: 553-78.
20. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102:17-24.
21. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489-96.
22. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002;360:516-20.
23. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107: 3738-44.
24. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005;90:1309-14.
25. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-7.
26. Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 2006;91:1187-92.
27. Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006;91:1241-3.
28. Nick H, Acklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J, et al. Development of tridentate iron chelators from desferrithiocin to ICL670. Curr Med Chem 2003; 10:1065-76.
29. Glickstein H, Ben El R, Link G, Breuer W, Konijn AM, Hershko C, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 2006;(Epub ahead of print).
30. Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 2001;97:1115-22.
31. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability and pharmacolinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron-overload due to β-thalassemia. J Clin Pharmacol 2003;43:565-72.
32. Nisbet-Brown E, Olivieri NT, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-602.
33. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006; 107: 3455-62.
34. Piga A, Galanello R, Forni GL et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006;91:873-80.
35. Porter JB, Tanner MA, Pennell DJ, Eleftheriou P. Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (Deferasirox) Blood 2005; 106:3600[abstract].